Skip to main content
. 2017 Aug 14;158(10):3629–3646. doi: 10.1210/en.2016-1617

Figure 3.

Figure 3.

Effect of long-term NVP-BGJ398 administration on growth and total body BMD and BMC in HMWTg mice. Starting at 5 weeks of age, HMWTg mice were treated with the FGFR inhibitor NVP-BGJ398 (50 mg/kg, oral) or vehicle three times per week for 8 weeks. Vector mice were treated with vehicle only. (a) Body weight, (b) tail length, (c) total body BMD, and (d) BMC were monitored. (e) Representative X-ray images of mice at 8 weeks after treatment showed dwarfism phenotype that was rescued with NVP-BGJ398. (f) Radiographs of excised femur from Vector or HMWTg mice treated with vehicle or NVP-BGJ398. (g) Quantification of femoral length. (h) Radiographs of excised tibia from Vector or HMWTg mice treated with vehicle or NVP-BGJ398. (i) Quantification of tibial length. Data are mean ± SE, n = 10 to 15 per group. *Vector-Vehicle vs HMWTg-Vehicle, P < 0.05; #Vector-Vehicle vs HMWTg-NVP-BGJ398, P < 0.05; @HMWTg-Vehicle vs HMWTg-NVP-BGJ398, P < 0.05.